Pulmonx Corp Stock Performance
LUNG Stock | USD 3.24 0.06 1.89% |
The company holds a Beta of 2.31, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pulmonx Corp will likely underperform. At this point, Pulmonx Corp has a negative expected return of -0.61%. Please make sure to check Pulmonx Corp's potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Pulmonx Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Pulmonx Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Actual Historical Performance (%)
One Day Return 1.89 | Five Day Return 1.25 | Year To Date Return (50.31) | Ten Year Return (91.76) | All Time Return (91.76) |
1 | Disposition of 385 shares by Geoffrey Rose of Pulmonx Corp at 6.97 subject to Rule 16b-3 | 05/02/2025 |
2 | Disposition of 20000 shares by Glendon French of Pulmonx Corp at 6.52 subject to Rule 16b-3 | 05/12/2025 |
3 | Disposition of 1724 shares by Geoffrey Rose of Pulmonx Corp at 6.97 subject to Rule 16b-3 | 05/15/2025 |
4 | Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference LUNG Stock News | 05/28/2025 |
5 | Trading With Integrated Risk Controls - news.stocktradersdaily.com | 06/03/2025 |
6 | Pulmonx Co. CEO Steven S. Williamson Sells 9,923 Shares of Stock | 06/05/2025 |
7 | BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness | 06/10/2025 |
8 | Disposition of 8000 shares by Ferrari Richard of Pulmonx Corp at 3.16 subject to Rule 16b-3 | 06/12/2025 |
9 | Pulmonx Director Cashes In on Stock Sale - TipRanks | 06/13/2025 |
10 | Shareholders May Not Overlook Pulmonx Insiders Selling US670k In Stock | 07/18/2025 |
11 | Pulmonx Corporation Stock Analysis and Forecast - High-profit stock alerts - jammulinksnews.com | 07/22/2025 |
Begin Period Cash Flow | 83.8 M | |
Total Cashflows From Investing Activities | 17.5 M |
Pulmonx Corp Relative Risk vs. Return Landscape
If you would invest 517.00 in Pulmonx Corp on April 24, 2025 and sell it today you would lose (193.00) from holding Pulmonx Corp or give up 37.33% of portfolio value over 90 days. Pulmonx Corp is currently does not generate positive expected returns and assumes 5.4034% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Pulmonx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Pulmonx Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pulmonx Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pulmonx Corp, and traders can use it to determine the average amount a Pulmonx Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1135
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | LUNG |
Estimated Market Risk
5.4 actual daily | 48 52% of assets are more volatile |
Expected Return
-0.61 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pulmonx Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pulmonx Corp by adding Pulmonx Corp to a well-diversified portfolio.
Pulmonx Corp Fundamentals Growth
Pulmonx Stock prices reflect investors' perceptions of the future prospects and financial health of Pulmonx Corp, and Pulmonx Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pulmonx Stock performance.
Return On Equity | -0.61 | ||||
Return On Asset | -0.22 | ||||
Profit Margin | (0.65) % | ||||
Operating Margin | (0.65) % | ||||
Current Valuation | 96.27 M | ||||
Shares Outstanding | 40.26 M | ||||
Price To Book | 1.65 X | ||||
Price To Sales | 1.49 X | ||||
Revenue | 83.79 M | ||||
Gross Profit | 64.27 M | ||||
EBITDA | (50.79 M) | ||||
Net Income | (56.39 M) | ||||
Cash And Equivalents | 162.09 M | ||||
Cash Per Share | 4.35 X | ||||
Total Debt | 56.47 M | ||||
Debt To Equity | 0.15 % | ||||
Current Ratio | 9.43 X | ||||
Book Value Per Share | 1.93 X | ||||
Cash Flow From Operations | (31.54 M) | ||||
Earnings Per Share | (1.44) X | ||||
Market Capitalization | 130.43 M | ||||
Total Asset | 162.85 M | ||||
Retained Earnings | (467.56 M) | ||||
Working Capital | 111.81 M | ||||
About Pulmonx Corp Performance
By analyzing Pulmonx Corp's fundamental ratios, stakeholders can gain valuable insights into Pulmonx Corp's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pulmonx Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pulmonx Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 283.37 | 248.31 | |
Return On Tangible Assets | (0.35) | (0.37) | |
Return On Capital Employed | (0.42) | (0.44) | |
Return On Assets | (0.35) | (0.36) | |
Return On Equity | (0.66) | (0.62) |
Things to note about Pulmonx Corp performance evaluation
Checking the ongoing alerts about Pulmonx Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pulmonx Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Pulmonx Corp generated a negative expected return over the last 90 days | |
Pulmonx Corp has high historical volatility and very poor performance | |
Pulmonx Corp has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 83.79 M. Net Loss for the year was (56.39 M) with profit before overhead, payroll, taxes, and interest of 64.27 M. | |
Pulmonx Corp currently holds about 162.09 M in cash with (31.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.35, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Pulmonx Corp has a poor financial position based on the latest SEC disclosures | |
Over 91.0% of the company shares are owned by institutional investors | |
Latest headline from news.google.com: Pulmonx Corporation Stock Analysis and Forecast - High-profit stock alerts - jammulinksnews.com |
- Analyzing Pulmonx Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pulmonx Corp's stock is overvalued or undervalued compared to its peers.
- Examining Pulmonx Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pulmonx Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pulmonx Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pulmonx Corp's stock. These opinions can provide insight into Pulmonx Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pulmonx Stock analysis
When running Pulmonx Corp's price analysis, check to measure Pulmonx Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmonx Corp is operating at the current time. Most of Pulmonx Corp's value examination focuses on studying past and present price action to predict the probability of Pulmonx Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmonx Corp's price. Additionally, you may evaluate how the addition of Pulmonx Corp to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |